We’ve done a lot of work on quality improvement, such as enhancing recovery, reducing intestinal injury during and after surgery, and reducing infections after surgery, explained William Cliby, MD, consultant, division of gynecologic surgery, department of obstetrics & gynecology, Mayo Clinic.
We’ve done a lot of work on quality improvement, such as enhancing recovery, reducing intestinal injury during and after surgery, and reducing infections after surgery, explained William Cliby, MD, consultant, division of gynecologic surgery, department of obstetrics & gynecology, Mayo Clinic.
Transcript
What surgical quality improvement measure have you focused on to improve surgical outcomes for patients with ovarian cancer?
For us, it’s taken 2 shapes. One is to reduce the amount of residual disease in the patient at the end of their first surgery. We think that puts them in the best position to respond to chemotherapy. So, we’ve spent a lot of effort at our own place and the Society of Gynecologic Oncology has, as well, to try to improve the surgical quality. Leaving less residual disease, using upper abdominal resection techniques to get the best quality surgery.
More specifically, to the actual surgical event, is steps to reduce the complications after surgery. We’ve done a lot of work on quality improvement, whether it’s enhanced recovery, so faster recovery for patients, reducing intestinal injury during and after surgery, reducing infections after surgery as well. All of those things have allowed us to reduce our complication rate and so reduce the amount of poor outcomes relative to good outcomes.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More